|
1
|
Trowsdale J and Betz AG: Mother's little
helpers: Mechanisms of maternal-fetal tolerance. Nat Immunol.
7:241–246. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Munoz-Suano A, Hamilton AB and Betz AG:
Gimme shelter: The immune system during pregnancy. Immunol Rev.
241:20–38. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bonney EA and Brown SA: To drive or be
driven: The path of a mouse model of recurrent pregnancy loss.
Reproduction. 147:R153–R167. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ishida Y, Agata Y, Shibahara K and Honjo
T: Induced expression of PD-1, a novel member of the immunoglobulin
gene superfamily, upon programmed cell death. EMBO J. 11:3887–3895.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Okazaki T and Honjo T: PD-1 and PD-1
ligands: From discovery to clinical application. Int Immunol.
19:813–824. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nishimura H, Minato N, Nakano T and Honjo
T: Immunological studies on PD-1 deficient mice: Implication of
PD-1 as a negative regulator for B cell responses. Int Immunol.
10:1563–1572. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Carreno BM and Collins M: The B7 family of
ligands and its receptors: New pathways for costimulation and
inhibition of immune responses. Annu Rev Immunol. 20:29–53. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lázár-Molnár E, Yan Q, Cao E, Ramagopal U,
Nathenson SG and Almo SC: Crystal structure of the complex between
programmed death-1 (PD-1) and its ligand PD-L2. Proc Natl Acad Sci
USA. 105:10483–10488. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zak KM, Grudnik P, Magiera K, Dömling A,
Dubin G and Holak TA: Structural biology of the immune checkpoint
receptor PD-1 and its ligands PD-L1/PD-L2. Structure. 25:1163–1174.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nishimura H and Honjo T: PD-1: An
inhibitory immunoreceptor involved in peripheral tolerance. Trends
Immunol. 22:265–268. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dong H, Strome SE, Salomao DR, Tamura H,
Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Iwai Y, Ishida M, Tanaka Y, Okazaki T,
Honjo T and Minato N: Involvement of PD-L1 on tumor cells in the
escape from host immune system and tumor immunotherapy by PD-L1
blockade. Proc Natl Acad Sci USA. 99:12293–12297. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dong H and Chen L: B7-H1 pathway and its
role in the evasion of tumor immunity. J Mol Med (Berl).
81:281–287. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Freeman GJ, Long AJ, Iwai Y, Bourque K,
Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne
MC, et al: Engagement of the PD-1 immunoinhibitory receptor by a
novel B7 family member leads to negative regulation of lymphocyte
activation. J Exp Med. 192:1027–1034. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Carter L, Fouser LA, Jussif J, Fitz L,
Deng B, Wood CR, Collins M, Honjo T, Freeman GJ and Carreno BM:
PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells
and is overcome by IL-2. Eur J Immunol. 32:634–643. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gao L, Liu F, Tan L, Liu T, Chen Z and Shi
C: The immunosuppressive properties of non-cultured dermal-derived
mesenchymal stromal cells and the control of graft-versus-host
disease. Biomaterials. 35:3582–3588. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vanikar AV, Trivedi HL, Gopal SC, Kumar A
and Dave SD: Pre-transplant co-infusion of donor-adipose tissue
derived mesenchymal stem cells and hematopoietic stem cells may
help in achieving tolerance in living donor renal transplantation.
Ren Fail. 36:457–460. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hong J, Yeom HJ, Lee E, Han KH, Koo TY,
Cho B, Ro H, Oh KH, Ahn C and Yang J: Islet allograft rejection in
sensitized mice is refractory to control by combination therapy of
immune-modulating agents. Transpl Immunol. 28:86–92. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Foy TM, Aruffo A, Bajorath J, Buhlmann JE
and Noelle RJ: Immune regulation by CD40 and its ligand GP39. Annu
Rev Immunol. 14:591–617. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pinelli DF and Ford ML: Novel insights
into anti-CD40/CD154 immunotherapy in transplant tolerance.
Immunotherapy. 7:399–410. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Larsen CP, Alexander DZ, Hollenbaugh D,
Elwood ET, Ritchie SC, Aruffo A, Hendrix R and Pearson TC:
CD40-gp39 interactions play a critical role during allograft
rejection. Suppression of allograft rejection by blockade of the
CD40-gp39 pathway. Transplantation. 61:4–9. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Coenen JJ, Koenen HJ, van Rijssen E,
Hilbrands LB and Joosten I: Tolerizing effects of co-stimulation
blockade rest on functional dominance of CD4+CD25+ regulatory T
cells. Transplantation. 79:147–156. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vermeiren J, Ceuppens JL,
Haegel-Kronenberger H, De Boer M, Boon L and Van Gool SW: Blocking
B7 and CD40 co-stimulatory molecules decreases antiviral T cell
activity. Clin Exp Immunol. 135:253–258. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Im SH, Barchan D, Maiti PK, Fuchs S and
Souroujon MC: Blockade of CD40 ligand suppresses chronic
experimental myasthenia gravis by down-regulation of Th1
differentiation and up-regulation of CTLA-4. J Immunol.
166:6893–6898. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Law CL and Grewal IS: Therapeutic
interventions targeting CD40L (CD154) and CD40: The opportunities
and challenges. Adv Exp Med Biol. 647:8–36. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lewis KL and Reizis B: Dendritic cells:
Arbiters of immunity and immunological tolerance. Cold Spring Harb
Perspect Biol. 4:a0074012012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pardee AD, Yano H, Weinstein AM, Ponce AA,
Ethridge AD, Normolle DP, Vujanovic L, Mizejewski GJ, Watkins SC
and Butterfield LH: Route of antigen delivery impacts the
immunostimulatory activity of dendritic cell-based vaccines for
hepatocellular carcinoma. J Immunother Cancer. 3:322015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hui E, Cheung J, Zhu J, Su X, Taylor MJ,
Wallweber HA, Sasmal DK, Huang J, Kim JM, Mellman I and Vale RD: T
cell costimulatory receptor CD28 is a primary target for
PD-1-mediated inhibition. Science. 355:1428–1433. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Patsoukis N, Brown J, Petkova V, Liu F, Li
L and Boussiotis VA: Selective effects of PD-1 on Akt and Ras
pathways regulate molecular components of the cell cycle and
inhibit T cell proliferation. Sci Signal. 5:ra462012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Graf D, Müller S, Korthäuer U, van Kooten
C, Weise C and Kroczek RA: A soluble form of TRAP (CD40 ligand) is
rapidly released after T cell activation. Eur J Immunol.
25:1749–1754. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Banchereau J, Bazan F, Blanchard D, Brière
F, Galizzi JP, van Kooten C, Liu YJ, Rousset F and Saeland S: The
CD40 antigen and its ligand. Annu Rev Immunol. 12:881–922. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hanissian SH and Geha RS: Jak3 is
associated with CD40 and is critical for CD40 induction of gene
expression in B cells. Immunity. 6:379–387. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lutgens E, Cleutjens KB, Heeneman S,
Koteliansky VE, Burkly LC and Daemen MJ: Both early and delayed
anti-CD40L antibody treatment induces a stable plaque phenotype.
Proc Natl Acad Sci USA. 97:7464–7469. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Schönbeck U, Sukhova GK, Shimizu K, Mach F
and Libby P: Inhibition of CD40 signaling limits evolution of
established atherosclerosis in mice. Proc Natl Acad Sci USA.
97:7458–7463. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yin D, Ma L, Shen J, Byrne GW, Logan JS
and Chong AS: CTLA-41g in combination with anti-CD40L prolongs
xenograft survival and inhibits anti-gal ab production in GT-Ko
mice. Am J Transplant. 2:41–47. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Saito K, Sakurai J, Ohata J, Kohsaka T,
Hashimoto H, Okumura K, Abe R and Azuma M: Involvement of CD40
ligand-CD40 and CTLA4-B7 pathways in murine acute graft-versus-host
disease induced by allogeneic T cells lacking CD28. J Immunol.
160:4225–4231. 1998.PubMed/NCBI
|
|
37
|
Clark DA, Chaouat G, Arck PC, Mittruecker
HW and Levy GA: Cytokine-dependent abortion in CBA × DBA/2 mice is
mediated by the procoagulant fgl2 prothrombinase [correction of
prothombinase]. J Immunol. 160:545–549. 1998.PubMed/NCBI
|
|
38
|
Girardi G, Yarilin D, Thurman JM, Holers
VM and Salmon JE: Complement activation induces dysregulation of
angiogenic factors and causes fetal rejection and growth
restriction. J Exp Med. 203:2165–2175. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yadav AK, Chaudhari H, Shah PK and Madan
T: Expression and localization of collectins in feto-maternal
tissues of human first trimester spontaneous abortion and abortion
prone mouse model. Immunobiology. 221:260–268. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Clark DA: The importance of being a
regulatory T cell in pregnancy. J Reprod Immunol. 116:60–69. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Aluvihare VR, Kallikourdis M and Betz AG:
Regulatory T cells mediate maternal tolerance to the fetus. Nat
Immunol. 5:266–271. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
42
|
Saito S, Sasaki Y and Sakai M:
CD4(+)CD25high regulatory T cells in human pregnancy. J Reprod
Immunol. 65:111–120. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bacchetta R, Gregori S and Roncarolo MG:
CD4+ regulatory T cells: Mechanisms of induction and effector
function. Autoimmun Rev. 4:491–496. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kingsley CI, Karim M, Bushell AR and Wood
KJ: CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4-
and IL-10-dependent immunoregulation of alloresponses. J Immunol.
168:1080–1086. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gordon JR, Ma Y, Churchman L, Gordon SA
and Dawicki W: Regulatory dendritic cells for immunotherapy in
immunologic diseases. Front Immunol. 5:72014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Henriques HR, Rampazo EV, Gonçalves AJ,
Vicentin EC, Amorim JH, Panatieri RH, Amorim KN, Yamamoto MM,
Ferreira LC, Alves AM and Boscardin SB: Targeting the
non-structural protein 1 from dengue virus to a dendritic cell
population confers protective immunity to lethal virus challenge.
PLoS Negl Trop Dis. 7:e23302013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Nan CL, Lei ZL, Zhao ZJ, Shi LH, Ouyang
YC, Song XF, Sun QY and Chen DY: Increased Th1/Th2 (IFN-gamma/IL-4)
Cytokine mRNA ratio of rat embryos in the pregnant mouse uterus. J
Reprod Dev. 53:219–228. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Platt JL: New directions for organ
transplantation. Nature. 392 (6679 Suppl):S11–S17. 1998.
|
|
49
|
Lin H, Mosmann TR, Guilbert L,
Tuntipopipat S and Wegmann TG: Synthesis of T helper 2-type
cytokines at the maternal-fetal interface. J Immunol.
151:4562–4573. 1993.PubMed/NCBI
|
